ALXO
ALX Oncology·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 1
Bearish signal 1
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ALXO
Alx Oncology Holdings Inc.
A clinical-stage immuno-oncology company that develops immuno-oncology therapies for the treatment of cancer
Biological Technology
04/01/2020
07/17/2020
NASDAQ Stock Exchange
80
12-31
Common stock
323 Allerton Avenue, South San Francisco, California 94080
--
ALX Oncology Holdings Inc. Incorporated on April 1, 2020. The company is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block CD47 immune checkpoints and connect the innate and adaptive immune systems.
Company Financials
EPS
ALXO has released its 2025 Q3 earnings. EPS was reported at -0.36, versus the expected -0.37, beating expectations. The chart below visualizes how ALXO has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
